Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Takhzyro HAE Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentCignaPolicy IP0334

    Hereditary Angioedema - Takhzyro

    Customize your policy alerts

    Sign up for Cigna Policy IP0334 alerts

    Get alerted when Policy IP0334 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and benefit coverage for Takhzyro (lanadelumab-flyo) used to prevent attacks of hereditary angioedema due to C1-inhibitor deficiency. It applies to health benefit plans administered by Cigna, subject to the applicable benefit plan, laws, and individual clinical circumstances.

    Policy Summary
    PayerCigna
    PolicyHereditary Angioedema - Takhzyro
    Policy CodePolicy IP0334
    Change TypeMaterial revision
    Effective DateNovember 15, 2026
    Last ReviewNov 5, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document the applicable indication, dosing, laboratory, and specialist requirements for Takhzyro coverage.
    SourceLink
    POLICY UPDATE CHANGES

    Coverage now requires hereditary angioedema type I or type II due to C1-inhibitor deficiency, with low functional C1-inhibitor and low serum C4 levels at baseline.

    The prior requirement for low baseline C1-inhibitor antigenic levels was removed.

    Continuation therapy criteria were added for patients currently receiving Takhzyro prophylaxis.

    The specialist requirement was expanded to include a physician who specializes in treating HAE or related disorders.

    The prior explicit criterion prohibiting concomitant use with other FDA-approved HAE prophylactic treatments was removed from the approval criteria.

    The policy title and criteria changes documented for earlier revisions remain part of the revision history.

    1 year

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Approval duration
    300 mg/2 wkAge 12+ dose
    150 mg/2 wkAge 6–11 dose
    150 mg/4 wkUnder age 6 dose
    J0593Covered drug code
    I/II onlyCovered HAE subtype

    Coverage Criteria

    FDA-approved HAE prophylaxis

    Approve for 1 year when the patient meets ONE of the following pathways.

    Approval pathway

    • Initial therapy

      • Diagnostic criteria: Patient has both low functional C1-INH protein at baseline and lower-than-normal serum C4 at baseline.Functional C1-INH < 50% of normal; serum C4 below normal

        Values must be established according to laboratory reference values.

      • Specialist involvement: Medication is prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.
    • Continuation therapy

      • Diagnosis: Patient has a diagnosis of HAE type I or type II.

        HAE with normal C1-INH, also known as HAE type III, does not satisfy this requirement.

      • Clinical response: According to the prescriber, the patient has had a favorable clinical response since initiating Takhzyro prophylaxis compared with baseline.

        Examples include decreased HAE acute attack frequency, severity, or duration.

      • Specialist involvement: Medication is prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.

    Age-based dosing

    Approve ONE of the following dosing regimens.

    • Patients age 12 years or older: Administer 300 mg per subcutaneous injection no more frequently than once every 2 weeks.300 mg every 2 weeks or less frequently
    • Patients age 6 to under 12 years: Administer 150 mg per subcutaneous injection no more frequently than once every 2 weeks.150 mg every 2 weeks or less frequently
    • Patients younger than 6 years: Administer up to 150 mg per subcutaneous injection no more frequently than once every 4 weeks.Up to 150 mg every 4 weeks or less frequently

    Concomitant use of Takhzyro with another long-term HAE prophylactic therapy is considered not medically necessary. Examples include Cinryze, Haegarda, and Orladeyo.

    HAE with normal C1-INH, also known as HAE type III, does not satisfy the covered indication for Takhzyro. Coverage requires HAE type I or type II due to C1-inhibitor deficiency.

    Takhzyro used for any purpose other than prophylaxis for HAE due to C1-inhibitor deficiency is considered not medically necessary. This includes concomitant long-term use with another HAE prophylactic therapy, such as Cinryze, Haegarda, or Orladeyo.

    Coding

    Considered Medically Necessary HCPCS CodeHCPCSCovered
    J0593Injection, lanadelumab-flyo, 1 mg (Code may be used for Medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)
    Functional C1-INH protein
    ThresholdLess than 50% of normal at baseline, as defined by laboratory reference values
    Serum C4
    ThresholdLower than normal at baseline, as defined by laboratory reference values

    Provider Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of Takhzyro. Approval is based on meeting the applicable indication criteria and dosing requirements; extended approvals require continued compliance.

    Note

    Specialist Prescribing Requirement

    Takhzyro must be prescribed by or in consultation with an allergist/immunologist or a physician who specializes in HAE or related disorders.

    Documentation Required

    Required Clinical Documentation

    Submit documentation wherever the criteria indicate that documentation is required. Records must include patient-specific identifying information and may include the following:

    Background

    Takhzyro (lanadelumab-flyo) is a human monoclonal antibody that inhibits plasma kallikrein. It is indicated for prophylaxis to prevent hereditary angioedema attacks in patients aged 2 years and older.

    Definitions

    HAE due to C1-inhibitor deficiency
    DefinitionHereditary angioedema due to C1-inhibitor deficiency is classified as HAE type I or type II
    Functional C1-INH requirementFunctional C1-INH protein must be less than 50% of normal at baseline, as defined by laboratory reference values
    Serum C4 requirementSerum C4 must be lower than normal at baseline, as defined by laboratory reference values
    HAE with normal C1-INH
    DefinitionHereditary angioedema with normal C1-inhibitor is also known as HAE type III
    C1-INH statusC1-inhibitor is normal
    Coverage status

    Initial Therapy

    Initial therapy criteria

    Approve for 1 year when the patient meets BOTH initial therapy requirements.

    Initial therapy

    • Diagnostic confirmation: Patient has both low functional C1-INH protein at baseline and lower-than-normal serum C4 at baseline.Functional C1-INH < 50% of normal; serum C4 below normal

      Both values must be established according to laboratory reference values; documentation is required.

    • Specialist prescribing or consultation: Medication is prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.

    Continuation Therapy

    Continuation therapy criteria

    Approve for 1 year when the patient is currently receiving Takhzyro prophylaxis and meets ALL continuation requirements.

    Continuation therapy

    • HAE diagnosis: Patient has a diagnosis of HAE type I or type II.

      HAE with normal C1-INH, also known as HAE type III, does not qualify.

    • Favorable clinical response: According to the prescriber, the patient has had a favorable clinical response since initiating Takhzyro prophylaxis compared with baseline.

      Examples include decreased HAE acute attack frequency, severity, or duration.

    • Specialist prescribing or consultation: Medication is prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.

    Quantity Limits

    Takhzyro quantity limit
    AgePatients 12 years of age or older
    Dose300 mg per subcutaneous injection
    Maximum frequencyNo more frequently than once every 2 weeks
    Takhzyro quantity limit
    AgePatients 6 to under 12 years of age
    Dose150 mg per subcutaneous injection
    Maximum frequencyNo more frequently than once every 2 weeks
    Policy Summary
    PayerCigna
    PolicyHereditary Angioedema - Takhzyro
    Policy CodePolicy IP0334
    Change TypeMaterial revision
    Effective DateNovember 15, 2026
    Last ReviewNov 5, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document the applicable indication, dosing, laboratory, and specialist requirements for Takhzyro coverage.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider ActionsBackgroundDefinitionsInitial TherapyContinuation TherapyQuantity Limits
    • Chart notes
    • Laboratory records
    • Medical test results
    • Prescription claims records
    Documentation Required

    Baseline HAE Laboratory Results

    For initial therapy, submit baseline laboratory documentation showing both functional C1-INH below 50% of normal and lower-than-normal serum C4, as defined by the laboratory reference values.

    • Baseline functional C1-INH: < 50% of normal
    • Baseline serum C4: below the laboratory reference range
    Documentation Required

    Continuation Response Documentation

    For continuation therapy, document HAE type I or type II and a favorable clinical response since Takhzyro prophylaxis began compared with baseline. Favorable response may include fewer acute attacks, reduced attack severity, or shorter attack duration.

    • Diagnosis of HAE type I or type II [documentation required]
    • Prescriber documentation of favorable clinical response compared with baseline
    • If the patient is currently receiving Takhzyro but has not previously received approval through the Coverage Review Department, initial therapy criteria apply
    Denial Risk

    HAE Type III Not Covered

    Takhzyro is not covered for HAE with normal C1-INH, also known as HAE type III, because this diagnosis does not satisfy the coverage requirement for HAE type I or type II due to C1-INH deficiency.

    Denial Risk

    Concurrent HAE Prophylaxis

    Takhzyro is not medically necessary when used concomitantly with another long-term HAE prophylactic therapy. Other medications may be used for on-demand treatment of acute attacks or short-term procedural prophylaxis.

    • Examples of other HAE prophylactic therapies include Cinryze, Haegarda, and Orladeyo
    Denial Risk

    Unmet Authorization or Dosing Requirements

    Requests may be denied when prior authorization, diagnostic, specialist, documentation, or dosing requirements are not met. Doses outside the established regimens are reviewed case by case by a clinician, such as a Medical Director or Pharmacist.

    • Age 12 years or older: 300 mg subcutaneously no more frequently than once every 2 weeks
    • Age 6 to < 12 years: 150 mg subcutaneously no more frequently than once every 2 weeks
    • Age < 6 years: up to 150 mg subcutaneously no more frequently than once every 4 weeks
    • Approvals are limited to the policy duration; continuation requires continued satisfaction of criteria and dosing
    Billing Rule

    Verify Covered Codes Before Billing

    Claims submitted without the applicable covered diagnosis and/or procedure codes may be denied as not covered. Use the most appropriate codes in effect on the submission date and verify that the billed condition is covered under the policy.

    • Claims for services billed with diagnoses or conditions not covered under the policy are not reimbursable
    • Services not accompanied by covered codes may be denied
    HAE type III does not satisfy the coverage requirement for Takhzyro
    Takhzyro quantity limit
    AgePatients younger than 6 years of age
    DoseUp to 150 mg per subcutaneous injection
    Maximum frequencyNo more frequently than once every 4 weeks